Human herpesvirus 6A (HHV-6A) is a widespread double-stranded DNA virus belonging to the β-herpesvirus subfamily. It is primarily transmitted through saliva, with close contact being the primary route of infection. After initial infection, HHV-6A establishes lifelong latency in immune cells, particularly CD4+ T lymphocytes, monocytes, and neural tissue. Under immunosuppressive conditions, such as in transplant recipients or patients with HIV/AIDS, HHV-6A may reactivate. HHV-6A has been associated with a variety of diseases, including encephalitis, multiple sclerosis, and endocrine disorders, although its precise role in these conditions remains under investigation. The virus employs immune evasion strategies, such as downregulation of major histocompatibility complex (MHC) class I molecules, to persist in the host.
HHV-6A has a characteristic herpesvirus morphology, with an icosahedral capsid surrounded by a tegument and a lipid envelope studded with glycoproteins. The viral genome is a linear, double-stranded DNA molecule approximately 160 kilobase pairs (kbp) in length, containing over 100 open reading frames (ORFs). The genome is organized into unique regions (U) flanked by terminal direct repeats (DRs), which are essential for viral replication and latency. Key genes include those encoding glycoproteins (such as gH, gL, and gB), which facilitate host cell entry by binding to receptors such as CD46. The genome also contains genes involved in immune regulation (such as U21, which redirects MHC class II molecules to lysosomes) and latency maintenance. Unlike its closely related HHV-6B, HHV-6A exhibits distinct genetic variation, particularly in the immediate early (IE) and glycoprotein regions, which may contribute to differences in tropism and disease association.
Control of viral infection in the brain involves activation of microglia (brain macrophages that continuously monitor the central nervous system) and production of amyloid-β protein (Aβ) as an antimicrobial molecule. Recent findings suggest that HHV-6A may be involved in Alzheimer's disease (AD). Here, researchers evaluated the effects of HHV-6A infection on microglial Aβ expression and its activation state, which is determined by the expression of TREM2, ApoE, cytokines, and tau protein. They infected microglial cells, in monolayer and human peripheral blood monocyte-derived microglia (PBM-microglia) spheroid 3D model, with HHV-6A cell-free virus inocula with 100 genome equivalents per 1 cell. Efficient infection with HHV-6A was observed. The expression of Aβ 1-42 increased from 3 days after infection, while no significant induction was observed for the expression of Aβ 1-40. HHV-6A infection induced microglial activation (TREM2, IL-1β, ApoE) and migration. Tau secretion began 7 days after infection, and the proportion of phosphorylated forms continued to increase. These results suggest that microglia are tolerant to HHV-6A infection, which can induce Aβ expression and activation state.
Aβ is the main component of neuritic plaques and is one of the more important molecules associated with the pathogenesis of AD. Studies have shown that the presence of HSV-1 and HHV-6 rapidly induces the production of amyloid plaques within 24 to 48 hours. These results support the hypothesis that Aβ deposition and fibrillization may be an innate immune response to pathogens that can protect the brain under normal circumstances. To this end, the researchers evaluated the effect of HHV-6A on the expression of two Aβ isoforms (Aβ1-40 and Aβ1-42) that are more relevant to AD. Aβ1-42 expression increased during HHV-6A infection, and Aβ1-40 expression increased slightly (Figure 1a). Interestingly, immunofluorescence analysis showed that the gp116 late viral antigen co-localized with Aβ1-42 protein expression (Figure 1b), indicating that HHV-6A infection has a direct effect on Aβ1-42 induction.
HHV-6A spheroid infection was monitored by gp116 expression. The researchers confirmed the permissivity of microglia to HHV-6A infection by increased transcription of U42 IE viral genes and expression of gp116 late viral antigen (Figure 1c-e). The analysis also showed that with the increase in gp116 expression, Aβ1-42 expression also increased (Figure 1d). Interestingly, at higher magnification, Aβ deposition could be observed, which was particularly evident at 14 d.p.i. (Figure 1e, left panel).
Figure 1. Beta amyloid expression in HHV-6-infected microglial cells. (Bortolotti D, et al., 2019)
Customer Reviews
Save time
The HHV-6A (GS) virus from Creative Biogene provided exceptional purity and infectivity in our latency/reactivation assays. We appreciate the detailed characterization data included, which saved us significant validation time.
Write a Review